Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy
The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA). Interim data has shown sustained or deepening improvements in most participants across both cardiac and neurological measures of FA. This includes clinically meaningful improvement in the modified Friedreich Ataxia […]
Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy Read More »